Avidity Partners Management
Latest statistics and disclosures from Avidity Partners Management's latest quarterly 13F-HR filing:
- Top 5 stock holdings are XBI, ARGX, UTHR, NBIX, AKRO, and represent 26.31% of Avidity Partners Management's stock portfolio.
- Added to shares of these 10 stocks: XBI (+$214M), MDGL (+$125M), UHS (+$116M), SGRY (+$79M), JAZZ (+$65M), PRTA (+$59M), ARGX (+$51M), LEGN (+$48M), PCVX (+$47M), RARE (+$44M).
- Started 18 new stock positions in VTYX, DGX, RCKT, THC, BCAB, BHVN, MDGL, UHS, TWST, VIR. FATE, BNTX, LEGN, KPTI, ICLR, ISEE, RXDX, COLL.
- Reduced shares in these 10 stocks: , LLY (-$289M), , HUM (-$103M), VRTX (-$98M), ELV (-$94M), HZNP (-$92M), AVTR (-$89M), CTLT (-$68M), AXSM (-$67M).
- Sold out of its positions in ALNY, ATEC, ELV, APLS, AVTR, BGNE, BIIB, CTLT, CNC, COGT.
- Avidity Partners Management was a net seller of stock by $-584M.
- Avidity Partners Management has $4.6B in assets under management (AUM), dropping by -6.16%.
- Central Index Key (CIK): 0001791827
Tip: Access up to 7 years of quarterly data
Positions held by Avidity Partners Management consolidated in one spreadsheet with up to 7 years of data
Download as csv
Download as Excel
Portfolio Holdings for Avidity Partners Management
Avidity Partners Management holds 85 positions in its portfolio as reported in the December 2022 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price | |
|---|---|---|---|---|---|---|
| Spdr Ser Tr S&p Biotech Call Option (XBI) | 7.3 | $337M | +174% | 4.1M | 83.00 |
|
| Argenx Se Sponsored Adr (ARGX) | 5.1 | $237M | +27% | 625k | 378.83 |
|
| United Therapeutics Corporation (UTHR) | 4.7 | $218M | -19% | 786k | 278.09 |
|
| Neurocrine Biosciences (NBIX) | 4.6 | $213M | -4% | 1.8M | 119.44 |
|
| Akero Therapeutics (AKRO) | 4.5 | $210M | +22% | 3.8M | 54.80 |
|
| Prothena Corp SHS (PRTA) | 3.9 | $178M | +50% | 3.0M | 60.25 |
|
| Arvinas Ord (ARVN) | 3.7 | $169M | +13% | 5.0M | 34.21 |
|
| Boston Scientific Corporation (BSX) | 3.3 | $151M | +28% | 3.3M | 46.27 |
|
| Syndax Pharmaceuticals (SNDX) | 3.2 | $149M | +4% | 5.9M | 25.45 |
|
| Ultragenyx Pharmaceutical (RARE) | 3.0 | $139M | +45% | 3.0M | 46.33 |
|
| Sarepta Therapeutics (SRPT) | 3.0 | $137M | +11% | 1.1M | 129.58 |
|
| Madrigal Pharmaceuticals (MDGL) | 2.7 | $125M | NEW | 430k | 290.25 |
|
| Universal Hlth Svcs CL B (UHS) | 2.5 | $116M | NEW | 826k | 140.89 |
|
| Jazz Pharmaceuticals Shs Usd (JAZZ) | 2.5 | $116M | +128% | 728k | 159.31 |
|
| Zentalis Pharmaceuticals (ZNTL) | 2.2 | $104M | +21% | 5.2M | 20.14 |
|
| Acadia Healthcare (ACHC) | 2.1 | $96M | -16% | 1.2M | 82.32 |
|
| Surgery Partners (SGRY) | 1.9 | $87M | +1062% | 3.1M | 27.86 |
|
| Dex (DXCM) | 1.9 | $86M | +61% | 757k | 113.24 |
|
| Astrazeneca Sponsored Adr (AZN) | 1.8 | $81M | +113% | 1.2M | 67.80 |
|
| Eli Lilly & Co. (LLY) | 1.7 | $79M | -78% | 217k | 365.84 |
|
| Vaxcyte (PCVX) | 1.7 | $78M | +156% | 1.6M | 47.95 |
|
| Avidity Biosciences Ord (RNA) | 1.6 | $73M | +25% | 3.3M | 22.19 |
|
| Natera (NTRA) | 1.6 | $72M | +3% | 1.8M | 40.17 |
|
| Ideaya Biosciences (IDYA) | 1.5 | $70M | +2% | 3.8M | 18.17 |
|
| Immunocore Hldgs Ads (IMCR) | 1.4 | $66M | -44% | 1.2M | 57.07 |
|
| Altimmune Com New (ALT) | 1.4 | $66M | +48% | 4.0M | 16.45 |
|
| Revolution Medicines (RVMD) | 1.3 | $59M | +6% | 2.5M | 23.82 |
|
| Karuna Therapeutics Ord (KRTX) | 1.3 | $59M | -30% | 299k | 196.50 |
|
| Arrowhead Pharmaceuticals (ARWR) | 1.2 | $56M | +9% | 1.4M | 40.56 |
|
| Axsome Therapeutics (AXSM) | 1.1 | $52M | -56% | 670k | 77.13 |
|
| Vertex Pharmaceuticals Incorporated (VRTX) | 1.1 | $50M | -66% | 172k | 288.78 |
|
| Legend Biotech Corp Sponsored Ads (LEGN) | 1.0 | $48M | NEW | 970k | 49.92 |
|
| Kezar Life Sciences (KZR) | 1.0 | $48M | +25% | 6.8M | 7.04 |
|
| Pliant Therapeutics (PLRX) | 0.9 | $43M | +13% | 2.2M | 19.33 |
|
| Ventyx Biosciences (VTYX) | 0.9 | $42M | NEW | 1.3M | 32.79 |
|
| Icon SHS (ICLR) | 0.9 | $42M | NEW | 215k | 194.25 |
|
| Quest Diagnostics Incorporated (DGX) | 0.9 | $40M | NEW | 258k | 156.44 |
|
| Bio Rad Labs Cl A (BIO) | 0.8 | $39M | -36% | 92k | 420.49 |
|
| Bellus Health Com New (BLU) | 0.8 | $38M | +5% | 4.6M | 8.22 |
|
| Tenet Healthcare Corp Com New (THC) | 0.8 | $35M | NEW | 717k | 48.79 |
|
| Karyopharm Therapeutics (KPTI) | 0.7 | $33M | NEW | 9.6M | 3.40 |
|
| Biontech Se Sponsored Ads (BNTX) | 0.7 | $32M | NEW | 215k | 150.22 |
|
| Verve Therapeutics (VERV) | 0.7 | $30M | +50% | 1.6M | 19.35 |
|
| Rocket Pharmaceuticals (RCKT) | 0.6 | $30M | NEW | 1.5M | 19.57 |
|
| Intra Cellular Therapies (ITCI) | 0.6 | $27M | -64% | 504k | 52.92 |
|
| Arcutis Biotherapeutics (ARQT) | 0.6 | $26M | +120% | 1.8M | 14.80 |
|
| Prometheus Biosciences (RXDX) | 0.5 | $22M | NEW | 204k | 110.00 |
|
| Intellia Therapeutics (NTLA) | 0.5 | $22M | -36% | 638k | 34.89 |
|
| Vir Biotechnology (VIR) | 0.5 | $22M | NEW | 850k | 25.31 |
|
| Phathom Pharmaceuticals (PHAT) | 0.5 | $21M | 1.9M | 11.22 |
|
|
| Biohaven (BHVN) | 0.4 | $21M | NEW | 1.5M | 13.88 |
|
| Cytokinetics Com New (CYTK) | 0.4 | $19M | +25% | 421k | 45.82 |
|
| Deciphera Pharmaceuticals (DCPH) | 0.4 | $19M | -5% | 1.1M | 16.39 |
|
| Caribou Biosciences (CRBU) | 0.4 | $18M | -9% | 2.9M | 6.28 |
|
| Iveric Bio (ISEE) | 0.4 | $18M | NEW | 838k | 21.41 |
|
| Point Biopharma Global (PNT) | 0.4 | $18M | -13% | 2.4M | 7.29 |
|
| Nanostring Technologies (NSTG) | 0.4 | $16M | +194% | 2.1M | 7.97 |
|
| Twist Bioscience Corp (TWST) | 0.3 | $15M | NEW | 611k | 23.81 |
|
| Bioatla (BCAB) | 0.2 | $10M | NEW | 1.3M | 8.25 |
|
| Compass Therapeutics (CMPX) | 0.2 | $10M | 2.0M | 5.03 |
|
|
| Sangamo Biosciences (SGMO) | 0.2 | $8.6M | +16% | 2.7M | 3.14 |
|
| Alpine Immune Sciences (ALPN) | 0.2 | $7.6M | +2% | 1.0M | 7.35 |
|
| Kinnate Biopharma (KNTE) | 0.2 | $7.4M | 1.2M | 6.10 |
|
|
| An2 Therapeutics (ANTX) | 0.2 | $7.1M | 744k | 9.53 |
|
|
| Century Therapeutics (IPSC) | 0.1 | $6.7M | 1.3M | 5.13 |
|
|
| Medicus Sciences Acquisition Cl A Shs | 0.1 | $5.2M | 520k | 10.07 |
|
|
| Graphite Bio (GRPH) | 0.1 | $5.2M | 1.6M | 3.32 |
|
|
| Arya Sciences Acqu Corp Iv Cl A (ARYD) | 0.1 | $5.1M | 500k | 10.10 |
|
|
| Panacea Acquisition Corp Ii Cl A Shs (PANA) | 0.1 | $5.0M | 500k | 10.05 |
|
|
| Essa Pharma Com New (EPIX) | 0.1 | $4.7M | -24% | 1.9M | 2.52 |
|
| Health Sciences Acq Corp 2 Ord Shs | 0.1 | $4.0M | 400k | 9.98 |
|
|
| Syros Pharmaceuticals Com New (SYRS) | 0.1 | $3.2M | 900k | 3.59 |
|
|
| Cyteir Therapeutics (CYT) | 0.1 | $3.0M | 1.8M | 1.65 |
|
|
| Caremax Com Cl A (CMAX) | 0.1 | $2.8M | 755k | 3.65 |
|
|
| Social Cap Suvretta Hlds Crp Class A Ord Shs (DNAB) | 0.0 | $2.0M | 200k | 10.06 |
|
|
| Social Cap Suvretta Hlds Cp Class A Ord Shs (DNAD) | 0.0 | $2.0M | 200k | 10.05 |
|
|
| Scynexis Com New (SCYX) | 0.0 | $1.8M | 1.1M | 1.56 |
|
|
| Hyperfine Com Cl A (HYPR) | 0.0 | $1.3M | 1.5M | 0.84 |
|
|
| Fate Therapeutics (FATE) | 0.0 | $1.1M | NEW | 105k | 10.09 |
|
| Zai Lab Adr (ZLAB) | 0.0 | $961k | -97% | 31k | 30.70 |
|
| Collegium Pharmaceutical Inc Common Stock Usd (COLL) | 0.0 | $879k | NEW | 38k | 23.20 |
|
| Ac Immune Sa SHS (ACIU) | 0.0 | $664k | +18% | 325k | 2.04 |
|
| Reunion Neuroscience (REUN) | 0.0 | $504k | -5% | 560k | 0.90 |
|
| Nuvation Bio *w Exp 07/07/202 (NUVB.WS) | 0.0 | $14k | 100k | 0.14 |
|
|
| Medicus Sciences Acquisition *w Exp 02/12/202 | 0.0 | $5.2k | 58k | 0.09 |
|
Past Filings by Avidity Partners Management
SEC 13F filings are viewable for Avidity Partners Management going back to 2019
- Avidity Partners Management 2022 Q4 filed Feb. 14, 2023
- Avidity Partners Management 2022 Q3 filed Nov. 14, 2022
- Avidity Partners Management 2022 Q2 filed Aug. 15, 2022
- Avidity Partners Management 2022 Q1 filed May 16, 2022
- Avidity Partners Management 2021 Q4 filed Feb. 14, 2022
- Avidity Partners Management 2021 Q3 filed Nov. 15, 2021
- Avidity Partners Management 2021 Q2 filed Aug. 16, 2021
- Avidity Partners Management 2021 Q1 filed May 17, 2021
- Avidity Partners Management 2020 Q4 filed Feb. 16, 2021
- Avidity Partners Management 2020 Q3 filed Nov. 16, 2020
- Avidity Partners Management 2020 Q2 filed Aug. 14, 2020
- Avidity Partners Management 2019 Q4 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 amended filed June 17, 2020
- Avidity Partners Management 2020 Q1 filed May 15, 2020
- Avidity Partners Management 2019 Q4 filed Feb. 14, 2020